These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8931886)

  • 1. Comparison of binding of 3H-desmethoxyverapamil and 3H-mibefradil in vascular smooth muscle and heart membranes. Possible binding of mibefradil to a site distinct from the phenylalkylamine-binding site.
    Ratner EI; Bochkov VN; Tkachuk VA
    Arzneimittelforschung; 1996 Oct; 46(10):953-5. PubMed ID: 8931886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of high affinity phenylalkylamine binding sites on cultured human embryonal vascular smooth muscle cells.
    Drímal J
    Gen Physiol Biophys; 1992 Dec; 11(6):555-65. PubMed ID: 1338048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines.
    Reynolds IJ; Snowman AM; Snyder SH
    J Pharmacol Exp Ther; 1986 Jun; 237(3):731-8. PubMed ID: 3012067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
    Sarsero D; Fujiwara T; Molenaar P; Angus JA
    Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action.
    Osterrieder W; Holck M
    J Cardiovasc Pharmacol; 1989 May; 13(5):754-9. PubMed ID: 2472524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of spironolactone with (+)-[3H]-isradipine and (-)-[3H]-desmethoxyverapamil binding sites in vascular smooth muscle.
    Mironneau J; Sayet I; Rakotoarisoa L; Dacquet C; Mironneau C
    Br J Pharmacol; 1990 Sep; 101(1):6-7. PubMed ID: 2149292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marrubenol interacts with the phenylalkylamine binding site of the L-type calcium channel.
    El Bardai S; Hamaide MC; Lyoussi B; Quetin-Leclercq J; Morel N; Wibo M
    Eur J Pharmacol; 2004 May; 492(2-3):269-72. PubMed ID: 15178374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of (-)-desmethoxyverapamil on heart and vascular smooth muscle.
    Nawrath H; Raschack M
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1090-7. PubMed ID: 3656109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of the phenylalkylamine binding site in canine cardiac sarcolemmal membranes.
    Dumont L; Williams JS; Vaghy PL; Schwartz A
    Basic Res Cardiol; 1988; 83(4):369-75. PubMed ID: 2847707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mibefradil--a new calcium-channel blocker.
    Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
    [No Abstract]   [Full Text] [Related]  

  • 12. (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile.
    Hofmann HP; Raschack M; Unger L
    Arzneimittelforschung; 1989 Mar; 39(3):304-8. PubMed ID: 2757655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the binding sites for nimodipine and (-)-desmethoxyverapamil in bovine cardiac sarcolemma.
    Ruth P; Flockerzi V; von Nettelbladt E; Oeken J; Hofmann F
    Eur J Biochem; 1985 Jul; 150(2):313-22. PubMed ID: 2990931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-affinity binding sites for [3H] verapamil in cardiac membranes.
    Hulthén UL; Landmann R; Bürgisser E; Bühler FR
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S291-3. PubMed ID: 6184555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ca2+-agonistic effect of a T-type Ca-channel blocker mibefradil (Ro 40-5967).
    Avdonin PV; Buhler FR; Tkachuk VA
    Membr Cell Biol; 2000; 13(5):645-55. PubMed ID: 10987388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle.
    Goll A; Ferry DR; Striessnig J; Schober M; Glossmann H
    FEBS Lett; 1984 Oct; 176(2):371-7. PubMed ID: 6092142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptors for diphenylbutylpiperidine neuroleptics in brain, cardiac, and smooth muscle membranes. Relationship with receptors for 1,4-dihydropyridines and phenylalkylamines and with Ca2+ channel blockade.
    Qar J; Galizzi JP; Fosset M; Lazdunski M
    Eur J Pharmacol; 1987 Sep; 141(2):261-8. PubMed ID: 2445589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
    Abernethy DR
    Am J Cardiol; 1997 Aug; 80(4B):4C-11C. PubMed ID: 9286848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular T-type calcium channels: physiological and pharmacological significance.
    Triggle DJ
    J Hypertens Suppl; 1997 Dec; 15(5):S9-15. PubMed ID: 9481611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue.
    Rutledge A; Triggle DJ
    Eur J Pharmacol; 1995 Jul; 280(2):155-8. PubMed ID: 7589180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.